Please login to the form below

Not currently logged in
Email:
Password:

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

NICE turns down Opdivo for adjuvant melanoma therapy

NICE turns down Opdivo for adjuvant melanoma therapy

England's cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor as an adjuvant treatment for NHS patients with stage III and IV melanoma – in ... At the moment Opdivo is the only PD-1-targeted cancer immunotherapy

Latest news

More from news
Approximately 21 fully matching, plus 246 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have. ... Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are

  • Deal Watch January 2018

    Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms. ... used to progress the clinical development of the company's immuno-oncology

  • The good, the bad and the ugly The good, the bad and the ugly

    But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Pharma deals continue to slide Pharma deals continue to slide

    1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US). ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for treatment of cancer.

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.

  • Immuno-oncology: The market opportunity for PD-1/PD-L1s

    Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1

  • Immuno-oncology: The market opportunity for PD-1/PD-L1s

    Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1

  • Research Partnership

    Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director. ... Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics